Bioventix logo

BVXP - Bioventix Share Price

4090p 10.0  0.2%

Last Trade - 9:54am

Small Cap
Market Cap £212.5m
Enterprise Value £206.7m
Revenue £10.2m
Position in Universe 823rd / 1819
Unlock BVXP Revenue
Relative Strength (%)
1m -7.10%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
4.33 5.52 7.25 8.75 9.29 10.3 11.1 +18.9%
+19.7 +37.0 +15.7 +14.4 +3.5 +23.0 -0.82
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, BioventixPLC revenues increased 1% to £5.2M. Net income decreased10% to £3.1M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Net income was offset by Difference on ForeignExchange increase from £80K (income) to £196K (expense),Share option charge increase from £67K to £138K (expense),Administrative Expenses increase of 7% to £689K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BVXP
Graphical History


BVXP Revenue Unlock BVXP Revenue

Net Income

BVXP Net Income Unlock BVXP Revenue

Normalised EPS

BVXP Normalised EPS Unlock BVXP Revenue

PE Ratio Range

BVXP PE Ratio Range Unlock BVXP Revenue

Dividend Yield Range

BVXP Dividend Yield Range Unlock BVXP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BVXP EPS Forecasts Unlock BVXP Revenue
Profile Summary

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated October 7, 2003
Public Since April 29, 2014
No. of Shareholders: n/a
No. of Employees: 16
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 5,209,333
Free Float (0.0%)
Eligible for
BVXP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BVXP
Upcoming Events for BVXP
Frequently Asked Questions for Bioventix
What is the Bioventix share price?

As of 9:54am, shares in Bioventix are trading at 4090p, giving the company a market capitalisation of £212.5m. This share price information is delayed by 15 minutes.

How has the Bioventix share price performed this year?

Shares in Bioventix are currently trading at 4090p and the price has moved by 8.06% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioventix price has moved by -12.1% over the past year.

What are the analyst and broker recommendations for Bioventix?

Of the analysts with advisory recommendations for Bioventix, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Bioventix is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Bioventix next release its financial results?

Bioventix is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bioventix dividend yield?

The Bioventix dividend yield is 2.33% based on the trailing twelve month period.

Does Bioventix pay a dividend?

Last year, Bioventix paid a total dividend of 0.95, and it currently has a trailing dividend yield of 2.33%. Looking ahead, Bioventix has not announced an ex-dividend date yet and the next dividend pay date is 2021-04-23.

When does Bioventix next pay dividends?

Bioventix has yet to annouce their ex-dividend date and the next dividend pay date is 2021-04-23. The historic dividend yield on Bioventix shares is currently 2.33%.

How do I buy Bioventix shares?

To buy shares in Bioventix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bioventix?

Shares in Bioventix are currently trading at 4090p, giving the company a market capitalisation of £212.5m.

Where are Bioventix shares listed? Where are Bioventix shares listed?

Here are the trading details for Bioventix:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: BVXP
What kind of share is Bioventix?

Based on an overall assessment of its quality, value and momentum, Bioventix is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bioventix share price forecast 2021?

Shares in Bioventix are currently priced at 4090p. At that level they are trading at 8.09% premium to the analyst consensus target price of 3,783.88.

Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of 1.368 for the next financial year.

How can I tell whether the Bioventix share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioventix. Over the past six months, the relative strength of its shares against the market has been -14.98%. At the current price of 4090p, shares in Bioventix are trading at -1.99% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bioventix PE Ratio?

The Bioventix PE ratio based on its reported earnings over the past 12 months is 31.72. The shares are currently trading at 4090p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bioventix?

Bioventix's management team is headed by:

P. Harrison - CEO
Ian Nicholson - NEC
Kim Tan - DRC
T. Turner - DRC
Nick McCooke - NED
Bruce Hiscock - CFO
Who are the major shareholders of Bioventix?

Here are the top five shareholders of Bioventix based on the size of their shareholding:

CFP SDL UK Buffettology Fund Mutual Fund
Percentage owned: 19.96% (1.04m shares)
Sanford DeLand Asset Management Limited Investment Advisor
Percentage owned: 18.91% (985k shares)
Liontrust Asset Management PLC Investment Advisor/Hedge Fund
Percentage owned: 9.92% (517k shares)
Canaccord Genuity Wealth Management Investment Advisor/Hedge Fund
Percentage owned: 9.83% (512k shares)
Liontrust UK Smaller Companies Fund Mutual Fund
Percentage owned: 8.87% (462k shares)
Similar to BVXP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.